AEON Biopharma Inc’s filing revealed that its Affiliate Oleg Grodnensky acquired Company’s shares for reported $0.53 million on Jul 29 ’24. In the deal valued at $2.63 per share,201,825 shares were bought.
H.C. Wainwright initiated its AEON Biopharma Inc [AEON] rating to a Buy in a research note published on August 18, 2023; the price target was $18.
Price Performance Review of AEON
On Friday, AEON Biopharma Inc [AMEX:AEON] saw its stock fall -9.89% to $0.15. Over the last five days, the stock has lost -17.03%. AEON Biopharma Inc shares have fallen nearly -71.48% since the year began. Nevertheless, the stocks have fallen -97.83% over the past one year. While a 52-week high of $17.17 was reached on 01/03/25, a 52-week low of $0.10 was recorded on 01/15/25. SMA at 50 days reached $0.5571, while 200 days put it at $1.6300.
Levels Of Support And Resistance For AEON Stock
The 24-hour chart illustrates a support level at 0.1359, which if violated will result in even more drops to 0.1177. On the upside, there is a resistance level at 0.1674. A further resistance level may holdings at 0.1807. The Relative Strength Index (RSI) on the 14-day chart is 27.65, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1636, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.01%. Stochastics %K at 8.24% indicates the stock is a buying.
How much short interest is there in AEON Biopharma Inc?
A steep rise in short interest was recorded in AEON Biopharma Inc stocks on 2024-11-15, growing by 11144.0 shares to a total of 0.16 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 0.15 million shares. There was a rise of 6.78%, which implies that there is a positive sentiment for the stock.
